



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/674,172	01/04/2000	Andreas Bohle	10890-2MIS-J	3048

24223 7590 05/23/2003

SIM & MCBURNEY
330 UNIVERSITY AVENUE
6TH FLOOR
TORONTO, ON M5G 1R7
CANADA

EXAMINER

ZEMAN, ROBERT A

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 05/23/2003

16

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/674,172

Applicant(s)

BOHLE ET AL.

Examiner

Robert A. Zeman

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 24 February 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4,8-16 and 20-23 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4,8-16 and 20-23 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ 6) ☐ Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 2-24-2003 has been entered.

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the

Art Unit: 1645

advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Claims 1-4, 8-16 and 20-23 are pending and currently under examination.

Claim Rejections Maintained

35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of claims 1-4, 8-12, 16 and 23 under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the use of **Bacillus Calmette-Guerin (BCG)** for the therapeutic treatment of condylomata acuminata, does not reasonably provide enablement for the use of **all Mycobacterium** species/strains for the therapeutic treatment of **all** disease conditions caused by papilloma virus infections is maintained for the reasons of record. Applicant has previously amended the claims to read only on the use of BCG in the treatment of disease conditions caused by papilloma virus infection. However, this amendment is insufficient to overcome the rejection since the specification does not provide enablement for the use of any *Mycobacterium* strains/species for the treatment of **all** disease conditions caused by papilloma virus infections. The specification provides ample factual evidence that BCG can be used to treat condylomata acuminata, which is associated with papilloma virus infection. Applicant has failed **b** give direction on what disease conditions, other than condylomata acuminata, would meet the limitations of the claims and has provided no evidence that any benefit to the treated subject

Art Unit: 1645

would be obtained from treatment with BCG. Human papilloma virus is associated with a myriad of human "disease conditions" including: verruca plantaris, verruca vulgaris, verruca plana, epidermodysplasia verruciformis (benign and squamous cell carcinoma), condyloma acuminatum, laryngeal papilloma, Butcher's warts, focal epithelial hyperplasia, cervical intraepithelial neoplasia, cervical carcinoma, oral papilloma, flat warts, macular lesions, Bowen's disease, bladder carcinomas and bladder papillomas. Applicant has not taught how to use BCG to treat any of the aforementioned disease conditions. Given the lack of success in the art, the lack of working examples, and the unpredictability of the generation of a therapeutic response in a living organism, the specification, as filed, is not enabling for the use of BCG as a therapeutic treatment for any and all disease conditions caused by papilloma virus infections.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

The rejection of claims 1-4 and 8-15 under 35 U.S.C. 112, second paragraph, as being vague and indefinite as they are lacking in positive active steps of the method, is maintained for reasons outlined in the rejection of claims 1-15 in the previous Office action. Applicant has failed to address this rejection in his response to the previous Office action.

The rejection of claims 1, 11-13 and 16 under 35 U.S.C. 112, second paragraph, as being rendered vague and indefinite by the use of the term "area of infection" is maintained for reasons of record. It is still unclear what Applicant is referring to. Is the "area of infection" the

site of papilloma virus infection or some other infection facilitated by the papilloma virus infection?

The rejection of claim 1 under 35 U.S.C. 112, second paragraph, as being rendered vague and indefinite by the use of the term "treatment dose" is maintained for reasons of record. It is still unclear to what constitutes a "treatment dose". What criteria are used to ascertain whether a given dose is a "treatment dose"?

The rejection of claim 8 under 35 U.S.C. 112, second paragraph, as being rendered vague and indefinite by the confusing language used in reciting the multiple ranges that encompass the limitations of the claim is maintained for reasons of record. Applicant argues that said claim language is clear in scope. The aforementioned claim language is confusing making it impossible to determine the metes and bounds of the claimed invention should be rewritten so that there is a clear demarcation of each limitation.

35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The rejection of claims 1, 2 and 9 under 35 U.S.C. 102(b) as being anticipated by Herr et al. is maintained for reasons of record.

Applicant has previously argued:

1. Herr et al. is not concerned with the treatment of a papilloma virus disease condition but rather describes the treatment of superficial bladder tumors with topical instillation of BCG.
2. No cream is used.
3. Human papilloma virus is not associated with bladder carcinoma or bladder papillomas.
4. According to Westenend et al. (IDS-8) papilloma is used to describe grade 1 papillary tumor when referring to superficial bladder tumors.
5. According to Westenend et al. there is no association between papillary urothelial carcinoma (papillomas) and HPV-associated condyloma (warts).

Applicant's arguments have been fully considered and deemed to be non-persuasive.

As outlined in the previous Office action, the instant invention is drawn to methods of treating disease conditions (warts papillomas, carcinomas etc.) caused by the papilloma virus. Said method comprises the application of a composition comprising a *Mycobacterium* (bacillus Calmette-Guerin). The recited methods of use also recite the use of said composition as a topical cream whose use is preceded by ablative surgery of the region of infection (i.e. removal of papilloma etc.).

Herr et al. disclose a method of treating superficial bladder carcinomas and papillomas caused by human papilloma virus (HPV) with bacillus Calmette-Guerin (BCG). Herr et al. also disclose that the BCG treatment can follow the resection of the tumor (see materials and methods section beginning on page 22). Said disclosure anticipates all the limitations of the rejected claims.

Art Unit: 1645

The Westenend et al. reference deals with only 7 of the 70+ serotypes of HPV and cannot be used to buttress the argument that HPV has no association with bladder tumors or papillomas. As stated by Westenend et al. (see introduction on page 198) "HPV has been implicated in the pathogenesis of several human cancers". Additionally, Westenend et al. deal only with the possible role of "high risk HPV and not all the different serotypes. Additionally, Applicant is reminded that claims 1 and 9 are drawn to all papilloma viruses not just HPV.

In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., composition is a cream) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not

Art Unit: 1645

commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The rejection of claims 1-4, 8-16 and 20-23 under 35 U.S.C. 103(a) as being unpatentable over Herr et al. (Journal of Urology Vol. 141, pages 22-29, 1989) in view of Morton (GB2179858A) is maintained for reasons of record.

Applicant has previously argued:

1. Herr et al. is not concerned with the treatment of a papilloma virus disease condition but rather describes the treatment of superficial bladder tumors with topical instillation of BCG.
2. No cream is used.
3. Human papilloma virus is not associated with bladder carcinoma or bladder papillomas.
4. According to Westenend et al. (IDS-8) papilloma is used to describe grade 1 papillary tumor when referring to superficial bladder tumors.
5. According to Westenend et al. there is no association between papillary urothelial carcinoma (papillomas) and HPV-associated condyloma (warts).
6. There is no motivation to modify the composition described by Morten et al.

As outlined in the previous Office action, the instant invention is drawn to a composition for treating disease conditions (warts etc.) caused by the papilloma virus and methods of using a composition comprising a *Mycobacterium* (bacillus Calmette-Guerin)

Art Unit: 1645

and a keratolytic agent (salicylic acid). The recited methods of use of said composition include its use as a topical cream whose use is preceded by ablative surgery (laser) of the region of infection (i.e. removal of papilloma etc.).

Herr et al. disclose a method of treating superficial bladder carcinomas and papillomas caused by human papilloma virus (HPV) with bacillus Calmette-Guerin (BCG). Herr et al. also disclose that the BCG treatment can follow the resection of the tumor (see materials and methods section beginning on page 22). Herr et al. differs from the instant invention in that it does not disclose the use of BCG to treat condylomata acuminata (genital warts) nor does it explicitly disclose the use of a laser to ablate the wart before the onset of treatment (said use is a common surgical practices and hence is obvious) or the use of salicylic acid as keratolytic agent in the treatment composition. Morton discloses the use of salicylic acid as a keratolytic agent in a topical compound that can be used to treat viral skin diseases including condylomata acuminata (see page 2 lines 15-17). Morton further discloses that the salicylic acid may comprise "up to 15% by weight" of the composition (see page 1, line 32). Finally, Morton discloses multiple composition forms for the topical application of the composition including a concentrated solution, a gel and an ointment. Since the use of creams/gels/ointments is commonly used to deliver a therapeutic composition to a treatment site it would have been obvious to one of skill ⁱⁿ of the art to use the BCG, as disclosed by Herr et al., in a salicylic acid-containing topical cream/gel/ointment as disclosed by Morton in order to take advantage of the benefits of using a topical cream/gel (i.e. therapeutic composition adheres to area to be treated). One would expect the resulting composition to be an effective treatment for condylomata acuminata (warts) since BCG has been demonstrated to be an effective treatment for papillomas, as disclosed by Herr et al.), which also has human papilloma virus as a causative agent.

Art Unit: 1645

The Westenend et al. reference deals with only 7 of the 70+ serotypes of HPV and cannot be used to buttress the argument that HPV has no association with bladder tumors or papillomas. As stated by Westenend et al. (see introduction on page 198) "HPV has been implicated in the pathogenesis of several human cancers". Additionally, Westenend et al. deal only with the possible role of "high risk HPV and not all the different serotypes. Additionally, Applicant is reminded that claims 1 and 9 are drawn to all papilloma viruses not just HPV.

In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., composition is a cream) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

With regard to Applicants assertion there would be no motivation to modify the composition disclosed by Morton: the BCG containing composition of Herr et al. is being modified to take advantage of the benefits of using a topical cream/gel (disclosed by Morton).

Conclusion

No claim is allowed.

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE**

Art Unit: 1645

FINAL even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (703) 308-7991. The examiner can normally be reached on Monday- Thursday, 7am -5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (703) 308-3909. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Art Unit: 1645

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

178
LYNETTE R. F. SMITH
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Robert A. Zeman
May 20, 2003